Here’s our handpicked selection of the best interviews, blog posts, popular articles, and breaking biotech news of the last two weeks: Want a systematic overview of every organization chipping away at human aging right now? Then you’ll love this nearly 800-page report from the Biogerontology Research Foundation. Put it in your queue for bedtime reading….

Last week when we heard from Dr. Ristow, he turned the outdated notion of the “free radical theory of aging” on its head, and demonstrated that antioxidants like vitamin A and vitamin C aren’t all they’re cracked up to be. But if those supplements can’t help us, what can? Perhaps, says Ristow, the answer can…

Here’s our handpicked selection of the best blog posts, popular articles, and breaking biotech news of the last two weeks: Longevity enthusiasts don’t need to feel left out of the mainstream funding frenzy anymore–Y Combinator has put a $1 million bounty on the head of aging, an attractively large figure for up-and-coming startups. Want to…

Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible plastic armrest, and two thin tubes lead from your wrist to the slender white machine next to you, one tube delivering your blood to the machine’s mysterious…

Someday soon we may be able to replace tissues or entire organs with those grown from a patients’ own stem cells… but just how soon? What challenges do stem cell therapies face on the path of development, as they progress from the lab to the commercial world? James Peyer, investor and former stem cell biologist, answers below…

Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s future, you’ve potentially elevated your practice of medicine from imprecise art to exact science. The better the biomarkers in your arsenal, the more information you have to…

“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs ever get regulatory approval? It’s simple: just choose a “primary indication” to test your drug with. Of course, that choice itself is rather difficult when you’re considering a geroprotector. Here’s how investors think about it…

Ever hear about an exciting discovery in the biomedical world, then later wonder why it seemingly dropped off the face of the Earth? In fact, it’s par for the course for potential therapeutics to fail before they ever get off the ground, guided unwittingly by their enthusiastic champions straight into a boneyard strewn with the…

“At what age would you like to get Alzheimer’s?” This was the question posed by venture capitalist, former stem cell biologist and Geroscience co-founder James Peyer at TEDxStuttgart last week. Peyer became a devotee and champion of the anti-aging movement early in his life, and over his career he’s watched the field mature from a collection…

Keeping one eye on your calories, and the other on that delicious-looking pumpkin pie? Don’t worry–your Thanksgiving sins probably won’t hurt your longevity as long as you’re fasting sometimes. You can thank your gut bacteria. What do insulin resistance and 17th century Prague have in common? The first rare variant that dramatically increases human lifespan…

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD